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a b s t r a c t 
Background/purpose: Coagulation complications are frequent, unwanted occurrences in extracorporeal 
membrane oxygenation (ECMO) treatment, possibly influenced by the pump in the ECMO-circuit. We 
hypothesized that fewer complications would occur with a smaller, heparin-coated ECMO system with 
a centrifugal pump (CP) than with one with a roller pump (RP) and that after conversion, complication 
rates would decrease over time. 
Methods: This single-center, retrospective chart study included all first neonatal and pediatric ECMO 
runs between 2009 and 2015. Differences between groups were assessed with Mann–Whitney U tests 
and Kruskal–Wallis tests. Determinants of complication rates were evaluated through Poisson regression 
models. The CP group was divided into three consecutive groups to assess whether complication rates 
decreased over time. 
Results: The RP group comprised 90 ECMO runs and the CP group 82. Hemorrhagic complication rates 
were significantly higher with the CP than with the RP, without serious therapeutic consequences, while 
thrombotic complications rates were unaffected. Intracranial hemorrhage rates and coagulation-related 
mortality rates were similar. Gained experience with the CP did not improve complication rates or sur- 
vival over time. 
Conclusions: Although the CP seems safe, it does not seem beneficial over the RP. Further research is 
warranted on how pump type affects coagulation , taking into account the severity and implications of 
coagulation complications. 
Level of Evidence: Level III. 
© 2020 The Authors. Published by Elsevier Inc. 
















Extracorporeal membrane oxygenation (ECMO) treatment en-
tails the temporary use of an extracorporeal circulation for acute
respiratory and/or cardiac failure. The interaction between circu-
lating blood and the non-biological surface of the ECMO circuit ac-
tivates several inflammatory and coagulation cascades [1] . These
cascades and the shear stress induced by ECMO can cause throm-Abbreviations: ACT, activated clotting time; APTT, activated partial thromboplas- 
tin time; CNS, central nervous system; CP, centrifugal pump; DIC, disseminated in- 
travascular coagulation; ECMO, extracorporeal membrane oxygenation; ELSO, extra- 
corporeal life support oxygenation; RP, roller pump; UFH, unfractionated heparin; 
VA ECMO, veno-venous extracorporeal membrane oxygenation; VV ECMO, veno- 
arterial extracorporeal membrane oxygenation. 
Type of Study: Retrospective Comparative Study. 
∗ Corresponding author. 
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ton et al. showed that thrombotic events occur in 31% of pedi-
atric ECMO runs [2] . To counteract these cascades patients receive
continuous anticoagulation therapy, often unfractionated heparin
(UFH), increasing the risk of hemorrhagic complications. In ad-
dition to anticoagulation therapy, the hemorrhaging risk also in-
creases with extensive use or loss of coagulation factors following
the start of ECMO treatment [3] . Dalton et al. also showed that
hemorrhagic complications occurred in 38% of pediatric ECMO.
Both thrombotic and hemorrhagic events complicate ECMO treat-
ment and are important causes of morbidity and mortality in
neonatal and pediatric ECMO [ 2 , 4 ]. 
In the last decade, there has been a shift from the use of
roller pumps to centrifugal pumps in the ECMO circuit. Cen-
trifugal pumps offer several potential benefits, including smaller
circuit size, lower circuit priming volumes, less blood trauma,and a smaller surface area for interaction between blood and 
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non-biological surface [ 5–10 ]. A smaller surface area may result in
less activated inflammatory and coagulation mediators, thus influ-
encing the coagulation process. Despite these expectations, several
retrospective analyses of the Extracorporeal Life Support Oxygena-
tion (ELSO) registry data revealed increased odds of hemolysis with
centrifugal pumps compared to roller pumps but found no differ-
ence in survival to discharge [ 11 –13 ]. These studies lack informa-
tion on coagulation management and the potential learning effect
after the transition to a centrifugal pump. 
In this paper, we have outlined the differences in coagulation
complication rates and outcome after conversion from an ECMO
system with a roller pump to a new smaller, heparin-coated ECMO
system incorporated with a centrifugal pump in neonatal and pedi-
atric ECMO in a high-volume ECMO center. Coagulation complica-
tions were defined and categorized following the ELSO registry. We
hypothesized that with the new ECMO system with the centrifugal
pump fewer thrombotic and hemorrhagic complications would oc-
cur and that after implementing the centrifugal pump complication
rates would decrease over time with gained experience. 
2. Material and methods 
2.1. Study design and population 
We conducted a single-center, retrospective chart study with a
before-after design in a pediatric intensive care unit of a tertiary
children’s hospital, which serves as the national referral ECMO cen-
ter. The study was approved by the hospital’s medical ethics re-
view committee (MEC-2017-478). The study population consisted
of all first ECMO runs in children until the age of 18 years between
December 2009 and December 2015. Patients who received extra-
corporeal cardiopulmonary resuscitation (ECPR) and patients can-
nulated elsewhere who were not transferred to our hospital within
24 h were excluded from the analysis. ECPR was defined as the
rapid deployment of veno-arterial ECMO (VA-ECMO) during car-
diopulmonary resuscitation before the return of spontaneous circu-
lation in patients with cardiac arrest or when repetitive cardiac ar-
rests occurred without sustained return of spontaneous circulation.
The first 75 patients receiving ECMO treatment with the centrifu-
gal pump described in this study have also been used for another
multicenter retrospective study to assess the efficacy and overall
complication and survival rates of the Deltastream DP3 pump (Me-
dox Medizintechnik AG, Stolberg,Germany) [14] . While this study
demonstrated the efficacy of this pump, there is no information on
whether complication and survival rates actually improved by con-
version to this type of pump. 
2.2. ECMO circuit 
Our institute converted from an ECMO system with a roller
pump to a new ECMO system with a centrifugal pump over several
months at the end of 2011. In the roller pump group (RP group),
the ECMO circuit consisted of the Stockert SIII roller pump with
either the Medtronic 0800 silicon membrane oxygenator and the
Medtronic 1/4 ′′ heat exchanger for neonates or the Medtronic I-
2500-2A silicone membrane oxygenator with an integrated heat
exchanger for pediatric patients. The circuits had uncoated tubing.
Estimated priming volumes of 350 ml were used for neonates and
900 ml for pediatric patients. In the centrifugal pump group (CP
group), the ECMO circuit consisted of the Medos DP3 centrifugal
pump with either the Medos HILITE R © 800 LT with an integrated
heat exchanger or the Novalung iLA Activve Membrane Ventila-
tor (iLA activve Minilung petit kit, iLA activve Minilung kit or iLA
activve iLa) with an integrated heat exchanger. The circuits had
coated tubing. Estimated priming volumes of 225 ml were used for
neonates and 360 ml for pediatric patients. For both groups, thePlease cite this article as: Ö. Erdem, J.W. Kuiper, R.J. Houmes et al., Coagula
neonatal and pediatric extracorporeal membrane oxygenation, Journal of Peuncoated Hospal Multiflow 60 or 100 were used as hemofilters. In
the RP group, continuous veno-venous hemofiltration (CVVH) was
performed by default in every ECMO patient, as the ECMO circuit
was integrated with a hemofiltration system in order to transfuse
all blood products in an isovolemic manner. In the CP group, CVVH
was only applied when indicated, as it became apparent that less
transfusions (especially platelet transfusions) were required dur-
ing ECMO treatment. The ECMO circuit of the CP group there-
for did not include a hemofiltration system. Neonates underwent
VA cannulation surgically through the carotid artery and jugular
vein with an open technique or centrally in case of ECMO treat-
ment following cardiopulmonary bypass. The pediatric population
with a weight below 15 kg underwent VA cannulation surgically
through the carotid artery and jugular vein or centrally in case
of ECMO treatment following cardiopulmonary bypass. For the pe-
diatric population with a weight above 15 kg, the technique of
VA cannulation depended on the underlying disease and vascular
width assessed with ultrasound. 
2.3. Coagulation management 
Intravenous UFH was used as anticoagulation in both groups.
Dosages were adjusted based on activated clotting time (ACT) pre-
dominantly in the RP group or activated prothrombin time (APTT)
predominantly in the CP group. The target range for ACT was be-
tween 180 and 200 s. The target range for APTT was between 60
and 85 s if the patient was older than 1 year of age and had no
pre-existent coagulation disorders and between 85 and 120 s if the
patient was younger than 1 year of age or had present pre-existent
coagulation disorders. APTT target ranges were increased in case
of thrombus formation, increased d -dimers or hemolysis. APTT tar-
get ranges were lowered in case of surgery and hemorrhages. Fib-
rinogen, d -dimers, and platelets were measured on a daily basis
in both groups. Additionally, when dosages were based on APTT
levels, antifactor Xa, prothrombin time, factor V, and antithrombin
were measured on a daily basis and in case of unexpected changes
in APTT values. In both groups, administration of intravenous UFH
was stopped in case of life threatening or persistent bleeding. In
case of surgical procedures in the roller pump group, ACT target
ranges were lowered by 20 s through lowering of the intravenous
UHF infusion, platelet levels were lowered to 150 × 10 9 /L, and
tranexamic acid was started 24 h before surgery. For the centrifu-
gal pump, intravenous UFH was switched off prior to surgery and
restarted within 4 – 6 h after surgery. 
2.4. Data collection 
All data were routinely collected. Data were extracted from the
hospital charts and from the ELSO registry forms. Patient charac-
teristics including age, gender, weight, indication for ECMO, ECMO
type (VA-ECMO or veno-venous ECMO (VV-ECMO)), duration of
ECMO treatment, and the use of CVVH were collected. Also, all
laboratory values of ACT, APTT, fibrinogen, platelet count, and d -
dimers were collected. Daily UFH infusion rate (IU/kg/h) and daily
infusion rates of red blood cells, platelets and fresh frozen plasma
were collected. The primary outcomes were coagulation complica-
tions as defined by the ELSO registry including additional com-
plications which are not included in the ELSO registry (marked
with ( ∗) in the complications described below). Thrombotic com-
plications included mechanical clots (clots in oxygenator, bladder,
hemofilter or undefined mechanical clots), central nervous system
(CNS) infarction, and clotting in the pulmonary ( ∗), cardiovascular
( ∗), gastrointestinal, and renal systems ( ∗). Bleeding complications
included CNS hemorrhages, cannulation site hemorrhages, catheter
insertion site hemorrhages( ∗), surgical site hemorrhages, hemolysistion complications after conversion from roller to centrifugal pump in 
diatric Surgery, https://doi.org/10.1016/j.jpedsurg.2020.11.018 
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(free hemoglobin > 50 mg/dl), disseminated intravascular coagula-
tion (DIC), and hemorrhages in the pulmonary, cardiovascular, gas-
trointestinal systems, and in the urogenital ( ∗) and ear/nose/throat
area ( ∗). Individual complication rates were corrected for duration
of the ECMO run to assess median complication rates per 7 days.
Survival to discharge and cause of death were assessed. To as-
sess the impact of inexperience after the implementation of a new
ECMO system and of the increase of experience over time on the
complication rate and outcome, the CP group was equally divided
into three consecutive groups (first CP group: n = 28; second CP
group: n = 27; third CP group: n = 27) and analyzed. 
2.5. Statistical analysis 
Continuous data are presented as median (interquartile range)
and categorical data as frequency (% of ECMO runs). For the com-
parison between RP group and CP group and for the comparison of
the three consecutive groups that used the CP, the Mann–Whitney
U test and the Kruskal–Wallis test for continuous variables and the
Pearson chi-square and Fisher’s exact test for categorical variables
were used. If the null hypothesis of the Kruskal-Wallis test was re-
jected, post-hoc analysis was performed with the Dunn’s test for
pairwise comparisons. The Bonferroni correction was then applied
to correct for multiple testing. The Spearman rank correlation coef-
ficient was calculated to assess the correlation between the num-
ber of coagulation complications per ECMO run and the duration
of the ECMO run. To correct the number of coagulation compli-
cations for ECMO duration, the number of coagulation complica-
tions was divided by the duration of the ECMO run (unit: days)
and multiplied by 7 to assess the coagulation complication rate per
7 days ECMO run. Multivariable Poisson regression models were
built for the number of coagulation complications, the number of
thrombotic complications, and the number of hemorrhagic compli-
cations to assess which variables were relevant in the development
of complications. The following covariates were considered in the
Poisson regression models: ECMO group (RP group or CP group),
type of ECMO (VV-ECMO or VA-ECMO), ECMO indication (cardiac
or pulmonary indication), surgery on ECMO, use of CVVH, and age
category (pediatric patient or neonate). The time at risk in the
Poisson regression models was the duration of the ECMO run. To
account for possible variation in risk over time, the models for the
number of coagulation complications and the number of hemor-
rhagic complications included the natural logarithm and the square
root of the natural logarithm of the duration of ECMO run as co-
variates. As there was no variation in risk over time for thrombotic
complications, the model for the number of thrombotic complica-
tions did not include these covariates. The model fit of the final
models was evaluated using the Pearson chi-square goodness-of-
fit test, and we assessed the possibility of overdispersion by com-
paring the values of the Akaike information criterion between the
Poisson regression model and the corresponding negative binomial
regression model. As part of a sensitivity analysis, secondary mod-
els were built by adding Year of ECMO treatment and its interac-
tion effect with ECMO group to the final models, to account for
possible change in patient care over time. In this sensitivity anal-
ysis the combined main effect of CP group and the interaction be-
tween Year of Treatment and CP group was tested with a likelihood
ratio test. A two-sided p-value of less than 0.05 was considered
statistically significant. SPSS version 21.0.0.1 (SPSS Inc, Chicago, IL)
was used for statistical analysis. 
3. Results 
3.1. Demographics 
Two hundred and three ECMO runs were performed in the
study period. 26 ECPR runs, four second ECMO runs, and a sin-Please cite this article as: Ö. Erdem, J.W. Kuiper, R.J. Houmes et al., Coagula
neonatal and pediatric extracorporeal membrane oxygenation, Journal of Pegle ECMO run performed mostly elsewhere were excluded from
the analysis. One hundred and seventy-two ECMO runs were an-
alyzed, with 90 runs in the RP group (until February 2012) and 82
in the CP group (from September 2011 onwards). Table 1 shows
the demographics per pump group. Except for more VA-ECMO
runs in the RP group, 60.0% versus 46.3% ( p = 0.046), and the
greater use of CVVH in the RP group, 96.7% versus 29.3% ( p < 0.001),
there were no significant differences between the two groups. Both
groups had comparable numbers of patients with congenital di-
aphragmatic hernia, 20% in the RP group vs. 21% in the CP group
( p = 0.527). The RP group had 1 (1.1%) oncological patient while
the CP group had 5 (6.1%) oncological patients ( p = 0.075). The
surgeries that patients underwent during ECMO runs are listed in
Supplementary Table 1. A large part was made up of patients who
underwent surgical repair for congenital diaphragmatic hernia. 
3.2. Coagulation management 
In Table 2 , laboratory values and UFH and transfusion rates per
pump group are listed. The CP group showed significantly lower
APTT values and higher fibrinogen and maximum d -dimers levels
while receiving less platelets than the RP group. Lower UFH infu-
sion rates were applied in the pediatric patients of the CP group
than of the RP group. 
3.3. Coagulation complications 
As summarized in Table 3 , the CP group showed significantly
more coagulation complications and more ECMO runs with coagu-
lation complications than the RP group. The number of coagulation
complications per ECMO run was weakly correlated with the dura-
tion of ECMO treatment ( ρ= 0.460; p < 0.001). After correcting for
duration, the CP group also showed significantly higher coagula-
tion complication rates than the RP group. The pediatric patients
in the RP group showed a median coagulation complication rate
per 7 days ECMO of 0.47 (0–1.68) versus a median rate of 1.13 (0–
2.65) in the CP group ( p = 0.020). The difference was owing to
a higher incidence of hemorrhagic complications in the CP group,
as the pediatric patients showed a higher incidence of cannulation
site bleedings, hemolysis, DIC and hemorrhages from the ENT-area.
Notably, the increased incidence of hemolysis was not accompa-
nied by a significantly increased number of ECMO runs with circuit
changes as shown in table 1 . The two groups showed comparable
numbers of ECMO runs with thrombotic complications and throm-
botic complications rates per 7 days ECMO. Also, intracranial hem-
orrhage rates in both groups were similar (5.6% vs 7.3%, p = 0.637).
Table 4 summarizes the adjusted rate ratios from the multi-
variable Poisson regression analysis. The CP group showed an in-
creased coagulation complication rate by a rate ratio of 1.788 com-
pared to the RP group (95% CI: 1.295–2.468). Undergoing surgery
while on ECMO treatment increased the coagulation complication
rate by 1.954 times (95% CI: 1.382–2.763). Type of ECMO, ECMO
indication, use of CVVH, and age category had no significant ef-
fect on coagulation complication rates. Separating thrombotic and
hemorrhagic complications revealed that hemorrhagic complica-
tion rates were 2.605 times greater in the CP group than in the
RP group (95% CI: 1.671–4.059). Hemorrhagic complication rates
were also 2.022 times higher if a patient underwent surgery while
on ECMO treatment (95% CI: 1.274–3.210). Thrombotic complica-
tion rates were 1.778 times higher if patients were treated with VA
ECMO than with VV ECMO (95% CI: 1.064–2.972) and 1.621 times
higher if a patient underwent surgery while on ECMO treatment
(95% CI: 1.046–2.514). Supplementary Table 2 summarizes the sen-
sitivity analyses for the Poisson regression analyses. After adjust-
ment for Year of treatment , the combined main effect of CP group
and the interaction between Year of Treatment and CP group did nottion complications after conversion from roller to centrifugal pump in 
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Table 1 
Patient characteristics per pump group. 
RP group CP group P -value 
ECMO runs 90 82 
Age (years) 0.067 (0.001–2.25) 0.323 (0.003–4.176) 0.557 
Neonate 48 (53.3%) 36 (43.9%) 0.217 
Gestational age of the neonatal population (weeks) 38.6 (37.5–39.9) 38.7 (38.0–40.4) 0.356 
Weight (kg) 3.8 (3.0–12.0) 5.2 (3.3–16.6) 0.072 
Male 50 (55.6%) 40 (48.8%) 0.374 
ECMO type 0.047 ∗
VV-ECMO 35 (38.9%) 42 (51.2%) 
VA-ECMO 54 (60.0%) 37 (45.1%) 
VV-ECMO converted to VA-ECMO 0 1 (1.2%) 
VA-ECMO converted to VV-ECMO 1 (1.1%) 0 
VV-ECMO converted to VA-ECMO converted to VV-ECMO 0 2 (2.4%) 
Duration of ECMO run (hours) 176.4 (95.9–270.4) 124.0 (76.0–263.9) 0.205 
ECMO runs with circuit changes 13 (14.4%) 21 (25.6%) 0.066 
CVVH during ECMO run 87 (96.7%) 24 (29.3%) < 0.001 ∗
Surgery during ECMO run 31 (34.4%) 18 (22.0%) 0.070 
Table 2 
Laboratory values and heparin infusion and transfusion rates per pump group. 
RP group CP group 
N Median (IQR) N Median (IQR) P -value 
ACT (s) 86 175 (170 - 177) 54 179 (168 - 201) 0.170 
APTT (s) 84 149 (101 - 180) 82 81 (71 - 109) < 0.001 ∗
Fibrinogen (g/L) 90 2.1 (1.6 – 2.9) 81 2.6 (1.8 – 3.8) 0.047 ∗
Maximum value D -dimers (mg/L) 82 2.1 (0.9 – 8.0) 81 29.8 (9.3 – 59.7) < 0.001 ∗
Platelet count (10 9 /L) 90 134.2 (111.8 – 134.3) 82 112.8 (94.8 – 147.1) 0.135 
UFH infusion rate (IU/kg/h) ° 89 40.1 (30.3 – 46.1) 82 34.5 (34.5 – 41.6) 0.010 ∗
UFH infusion rate in neonates (IU/kg/h) ° 48 40.1 (32.9 – 45.1) 36 37.9 (30.2 – 46.1) 0.678 
UFH infusion rate in pediatric patients (IU/kg/h) ° 41 40.1 (28.0 – 48.6) 46 29.1 (21.5 – 37.3) 0.008 ∗
Infusion of packed red blood cells (ml/kg/d) 90 0.47 (0.22 – 0.94) 82 0.50 (0.28 – 0.80) 0.646 
Infusion of fresh frozen plasma (ml/kg/d) 90 0.10 ( < 0.01 – 0.43) 82 0.18 ( < 0.01 – 0.77) 0.145 
Infusion of platelets (ml/kg/d) 90 1.11 (0.42 – 1.78) 82 0.53 (0.10 – 1.00) < 0.001 ∗
Table 3 
Coagulation complications during ECMO run and outcome per pump group. 
RP group CP group P -value 
ECMO runs 90 82 
ECMO runs with coagulation complications 46 (51.1%) 56 (68.3%) 0.014 ∗
Coagulation complications 99 140 
Coagulation complication rate per 7 days ECMO 0.34 ( < 0.01 – 1.68) 1.15 ( < 0.01 – 2.08) 0.010 ∗
ECMO runs with hemorrhagic complication(s) 30 (33.3%) 42 (51.2%) 0.018 ∗
Hemorrhagic complications 43 88 
Cannulation site bleeding 5 17 
Surgical site bleeding 11 12 
Gastrointestinal hemorrhage 6 7 
Hemolysis 3 21 
DIC 1 5 
Central nervous system hemorrhage 5 6 
Pulmonary hemorrhage 5 5 
Cardiovascular hemorrhage 4 3 
Urogenital hemorrhages 2 5 
Hemorrhages ear/nose/throat area 1 5 
Hemorrhages peripheral/arterial catheter 0 2 
Hemorrhagic complication rate per 7 days ECMO < 0.01 ( < 0.01 – 0.63) 0.38 ( < 0.01 – 1.39) 0.012 ∗
ECMO runs with thrombotic complication(s) 35 (38.9%) 35 (42.7%) 0.505 
Thrombotic complications 56 52 
Pulmonary clotting 2 4 
Cardiovascular clotting 5 4 
Central nervous system infarction 4 4 
Circuit-related thrombotic complications 45 40 
Thrombotic complication rate per 7 days ECMO < 0.01 ( < 0.01 – 0.72) < 0.01 ( < 0.01 – 0.83) 0.464 
ECMO runs with thrombotic and hemorrhagic complications 19 (21.1%) 20 (24.4%) 0.608 
Died on ECMO treatment 17 (19.9%) 23 (28.0%) 0.058 
Mortality owing to coagulation complications 5 (5.6%) 7 (8.5%) 0.477 
Survival to discharge 47 (52.2%) 51 (62.2%) 0.187 
Please cite this article as: Ö. Erdem, J.W. Kuiper, R.J. Houmes et al., Coagulation complications after conversion from roller to centrifugal pump in 
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Table 4 
Poisson regression models for number of coagulation complications. 
Model Dependent variable Covariate 
Adjusted 
rate ratios 95% CI P -value 
I Number of coagulation 
complications ∗
CP group (reference = RP group) 1.788 1.295–2.468 < 0.001 ∗∗
VA ECMO (reference = VV ECMO) 1.234 0.885–1.720 0.214 
Surgery on ECMO 1.954 1.382–2.763 < 0.001 ∗∗
Pulmonary ECMO indication (reference = cardiac ECMO 
indication) 
0.905 0.605–1.354 0.627 
CVVH 1.132 0.785–1.633 0.506 
Neonate 0.788 0.575–1.078 0.136 
II Number of thrombotic 
complications 
CP group (reference = RP group) 1.165 0.716–1.896 0.539 
VA ECMO (reference = VV ECMO) 1.778 1.064–2.972 0.028 ∗∗
Surgery on ECMO 1.621 1.046–2.514 0.031 ∗∗
Pulmonary ECMO indication (reference = cardiac ECMO 
indication) 
0.962 0.544–1.702 0.895 
CVVH 0.904 0.509–1.606 0.730 
III Number of hemorrhagic 
complications ∗
CP group (reference = RP group) 0.805 0.519–1.248 0.331 
VA ECMO (reference = VV ECMO) 2.605 1.671–4.059 < 0.001 ∗∗
Surgery on ECMO 0.934 0.600–1.453 0.761 
Pulmonary ECMO indication (reference = cardiac ECMO 
indication) 
2.022 1.274–3.201 0.003 ∗∗






































































significantly affect hemorrhagic complication rates or thrombotic
complication rates. These results imply that there was no signifi-
cant change in the level or the trend of these complication rates
after the introduction of the centrifugal pump. 
3.4. Outcome 
As shown in Table 3 , outcome did not significantly differ be-
tween the RP group and the CP group. In the RP group, 80.0%
were weaned from ecmo treatment versus 70.7% in the CP group
( p = 0.058). In the RP group, 52.2% survived to discharge versus
62.2% of the CP group ( p = 0.187). In addition, survival to dis-
charge did not significantly differ between the RP group and the
CP group when neonatal and pediatric groups were analyzed sep-
arately (neonatal: 50.0% versus 61.1%, p = 0.311; pediatric: 54.8%
versus 63%, p = 0.430). Five patients in the RP group (5.6%) and 7
patients in the CP group (8.5%) died owing to coagulation compli-
cations. In the RP group, 2 patients died owing to bleeding compli-
cations including 1 intracranial hemorrhage, 1 owing to an cerebral
infarction, and 2 owing to a combination of intracardiac thrombi
and intraabdominal hemorrhages. In the CP group, 5 patients died
owing to bleeding complications including 4 intracranial hemor-
rhages, while 2 patients died owing to pulmonary thrombotic com-
plications. 
3.5. Coagulation complications after conversion to centrifugal pump 
Table 5 displays the effects of experience on coagulation com-
plications after conversion to a new ECMO system with the cen-
trifugal pump. Baseline demographics did not significantly differ
between the three consecutive groups except for the number of
surgeries during ECMO runs, which increased over time. The num-
ber of ECMO runs with hemorrhagic complications did not signif-
icantly differ between the groups but the total number of hem-
orrhagic complications was threefold in the third group compared
to the first group. The second group had the highest incidence of
ECMO runs with thrombotic complications owing to an increase of
mechanical clotting. This was also apparent by the increase of the
number of ECMO runs with system changes and the higher maxi-
mum d -dimer values. The thrombotic complication rate was lower
in the third group than the second group, although it remainedPlease cite this article as: Ö. Erdem, J.W. Kuiper, R.J. Houmes et al., Coagula
neonatal and pediatric extracorporeal membrane oxygenation, Journal of Pehigher than in the first group. Correcting for ECMO duration re-
sulted in median coagulation complication rates which were not
significantly different for both hemorrhagic and thrombotic com-
plications between the three groups. The number of CNS hemor-
rhages and infarctions were comparable between the three groups.
Survival rates did not differ between the three groups ( p = 0.837).
Mortality owing to coagulation complications was lower in the last
group, but this difference was not significant ( p = 0.632). 
4. Discussion 
Our study has demonstrated that conversion from an ECMO
system with the roller pump to a new smaller and heparin-coated
ECMO system with the centrifugal pump increased hemorrhagic
complications rates. However, conversion did not significantly af-
fect the number of thrombotic complications, the number of circuit
changes, the occurrence of neurological complications (i.e. infarc-
tion or hemorrhage), survival, and, most importantly, mortality ow-
ing to coagulation complications. Inexperience with a new ECMO
system also did not seem to affect com plication rates or outcome,
as complication rates were comparable over the three consecutive
groups of patients treated with the centrifugal pump. 
The possible explanation for the increase of hemorrhagic com-
plications in the CP group is multifold. Hemorrhagic complications
in the CP group included hemolysis, cannulation site bleedings,
DIC, and hemorrhages in the ear/nose/throat area. As shown by for-
mer ELSO studies and ours, the use of centrifugal pump increases
hemolysis, possibly owing to shear stress. Neonatal and pediatric
ELSO data showed increased odds of hemolysis for patients under-
going support with centrifugal pumps [ 11 , 12 ]. Several retrospec-
tive studies have showed hemolysis to be a common complication
of centrifugal pumps and also associated with worse outcomes [ 13 ,
15 , 16 ]. In contrast, Dalton et al. performed a prospective cohort
study in 8 hospitals and did not find pump type to be associated
with bleeding, thrombosis, hemolysis or mortality [17] . Although
the centrifugal pump seems to increase the risk for hemolysis, the
CP group did not show more circuit changes or more thrombotic
complications compared to the RP group. Also, as free hemoglobin
was not always measured in the past, the increase of hemolysis
rates might be (partly) explained by more routine testing of free
hemoglobin in the CP group [13] . One should also point out thattion complications after conversion from roller to centrifugal pump in 
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Table 5 
Effect of experience after conversion to the centrifugal pump on coagulation complication rates and outcome. 
First CP group Second CP group Third CP group p -value 
ECMO-runs 28 27 27 
UFH infusion rate (IU/kg/h) 28.4 (21.9–40.8) 35.2 (27.7–40.8) 36.0 (26.0–46.7) 0.310 
Neonates 11 (39.3%) 12 (44.4%) 14 (51.9%) 0.593 
Duration ECMO run (hours) 90.7 (63.7–246.2) 137.5 (87.3–320.0) 153.3 (82.5–275.4) 0.345 
Surgery on ECMO 2 8 10 0.002 ∗
ECMO runs with system changes 3 12 6 0.015 ∗
APTT (s) 77 (70 – 77) 81 (73 – 102) 92 (71 – 109) 0.453 
Maximum D -dimers (mg/L) 21.1 (2.9–35.2) 67.4 (20.9–100.0) 15.0 (8.4–55.3) 0.002 ∗
ECMO type 0.708 
VV ECMO 16 (57.1%) 13 (48.1%) 15 (55.6%) 
VA ECMO 12 (42.9%) 14 (51.9%) 12 (44.4%) 
ECMO runs with coagulation complications 16 (57.1%) 20 (74.1%) 20 (74.1%) 0.460 
Coagulation complications 24 56 60 
Median coagulation complication rate per 7 days ECMO 0.604 ( < 0.001–1.809) 1.330 (0.738–2.100) 1.621 ( < 0.001–2.047) 0.142 
ECMO runs with hemorrhagic complication(s) 10 (35.7%) 17 (63.0%) 15 (55.6%) 0.111 
Hemorrhagic complications 14 31 43 
Cannulation site bleeding 6 6 5 
Surgical site bleeding 1 4 7 
Gastrointestinal hemorrhage 0 2 5 
Hemolysis 3 8 10 
DIC 0 4 1 
Central nervous system hemorrhage 3 2 1 
Pulmonary hemorrhage 0 2 3 
Cardiovascular hemorrhage 0 2 1 
Urogenital hemorrhages 1 0 4 
Hemorrhages ear/nose/throat area 0 1 4 
Hemorrhages peripheral/arterial catheter 0 0 2 
Median hemorrhagic complication rate per 7 days ECMO < 0.001 ( < 0.001–0.809) 0.622 ( < 0.001–1.575) 0.603 ( < 0.001–2.036) 0.112 
ECMO runs with thrombotic complication(s) 7 (25.0%) 17 (63.0%) 11 (40.7%) 0.034 ∗
Thrombotic complications 10 25 17 
Pulmonary clotting 0 3 1 
Cardiovascular clotting 2 1 1 
Central nervous system infarction 1 2 1 
Circuit-related thrombotic complications 7 19 14 
Median thrombotic complication rate per 7 days ECMO < 0.001 ( < 0.001–0.325) 0.386 ( < 0.001–1.222) < 0.001 ( < 0.001–0.649) 0.086 
ECMO runs with thrombotic and hemorrhagic complications 1 (3.6%) 14 (51.9%) 6 (22.2%) 0.001 ∗
Died on ECMO treatment 7 (25.0%) 8 (28.6%) 8 (28.6%) 0.929 
Mortality owing to coagulation complications 3 (10.7%) 3 (11.1%) 1 (3.7%) 0.632 






















































while the ELSO categorizes hemolysis as a hemorrhagic compli-
cation, it is not a true hemorrhagic complication. Hemolysis is a
sign of abnormal breakdown of red blood cells. In addition, over
time our ECMO patients were sedated less and mobilized much
earlier. The risk of hemorrhaging through manipulation and move-
ment could therefore have been higher in the CP group, a possible
explanation for the increase of cannulation site bleedings. Of the
5 patients who developed DIC, 3 suffered from (severe) sepsis. It
is more likely that the development of DIC was caused by sepsis
than the ECMO circuit. Thus, although the CP group showed more
hemorrhagic complications than the RP group, the consequences of
these complications were limited. However, follow-up studies are
necessary to further delineate long term sequelae. 
Multivariate analysis showed that both hemorrhagic and throm-
botic complication rates were affected by whether patients un-
derwent surgery during ECMO treatment. As UFH infusion was
ceased before surgery to prevent intraoperative hemorrhaging, this
could have increased the risk of thrombotic complications. As UFH
infusion was restarted after surgery while patients had surgical
wounds, this could have increased the risk of hemorrhagic com-
plications. 
During the study period, APTT instead of ACT was increasingly
used as leading coagulation parameter and separate UFH regimes
were used for neonatal and pediatric patients. Additional adjust-
ments to the coagulation protocol were made for special circum-
stances such as surgery. Despite the change in the leading coag-
ulation parameter, median ACT values were comparable between
the RP group and the CP group. While maximum values of d -Please cite this article as: Ö. Erdem, J.W. Kuiper, R.J. Houmes et al., Coagula
neonatal and pediatric extracorporeal membrane oxygenation, Journal of Pedimers were higher in the CP group than in the RP group, throm-
botic complication rates were comparable between the two groups.
As one could not adjust for UFH infusion rates in the regression
models, it is unclear whether and how the different UFH regimes
affected the development of coagulation complications. Although
lower UFH infusion rates were administered in pediatric patients of
the CP group, they showed higher hemorrhagic complication rates
than the RP group. Similarly, in adult patients, Halaweish et al.
found a higher incidence of non-surgical bleeding complications in
the CP group compared to the RP group despite higher UFH use in
the latter [18] . A possible explanation would be that owing to the
smaller ECMO circuit with the centrifugal pump and the less fre-
quent use of CVVH ECMO patients would require less UFH to pre-
vent thrombotic complications. However, our multivariable analysis
showed that the new ECMO system with the centrifugal pump or
the use of CVVH did not significantly affect thrombotic complica-
tion rates. Also, the increased hemolysis rates, responsible for the
largest part of the increase in complication rates, were not related
to UFH administration. 
To our knowledge, no pediatric studies have reported the im-
pact of conversion to a new ECMO system over time. The first
group of patients after conversion had the lowest number of co-
agulation complications. This could be explained by selection of
eligible patients during the introduction of the new pump. After
full conversion to the centrifugal pump the number of coagula-
tion complications increased. However, the number of coagulation
complications was associated with ECMO duration, as is appar-
ent by the comparable coagulation rates. The increase of the totaltion complications after conversion from roller to centrifugal pump in 
diatric Surgery, https://doi.org/10.1016/j.jpedsurg.2020.11.018 
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number of coagulation complications over time could then possi-
bly be explained by the longer ECMO runs in the second and third
groups. In our study, the inexperience that accompanies the con-
version to a new ECMO system with a different pump did not sig-
nificantly affect survival rates over time. 
Our study has several limitations. This was a retrospective sin-
gle center chart study with a limited number of patients. ELSO
studies included more patients, but comprised a more heteroge-
neous group of patients as these were treated by different centers
with different experience levels and different coagulation proto-
cols [ 12 , 13 ]. In contrast to these studies, we were able to study
ECMO circuit changes, administered UFH and different coagulation
parameters owing to the presence of one single treatment protocol.
Owing to the before-after study design, there is a possible bias, as
we could not account for changes, if any, in treatment (aside from
changes in the ECMO circuit) over time. However, the number of
patients in our study was limited as we wanted to include patients
who were treated in a short time period before and after the mo-
ment of conversion to a new pump. This would limit the possi-
ble, if any, other changes in treatment. In addition, the sensitivity
analyses of the regression model showed that Year of treatment
did not affect com plication rates, i.e. possible change in treatment
over the years showed no significant effect on complication rates.
Still, larger prospective studies are necessary to confirm our find-
ings. Owing to the retrospective character of the study, we were
not able to take into the account when the coagulation complica-
tions occurred during the ECMO run. However, statistical adjust-
ments were made to the multivariate models to account for the
possible variation in risk over time. We observed less VA ECMO
runs in the CP group than in the RP group. As similar indications
for type of ECMO treatment (VV of VA ECMO) were uphold dur-
ing the study period in both groups, we consider this finding to be
coincidental. Because of the limited number of patients, it was not
possible to perform a coagulation analysis for VV ECMO and VA
ECMO separately (as indications for ECMO treatment differed) and
for neonatal and pediatric patients separately (as indications for
ECMO treatment and management differed). Although these vari-
ables were included in the multivariate models in order to account
for possible differences between these groups, it could be disputed
whether this was sufficient. Because limited information on coag-
ulation complications and individual management on ECMO treat-
ment was documented in the time period before 2009, it was not
possible to collect data before 2009. For this reason, no a priori
power analysis was performed and a convenient sample size of the
last 100 patients in the RP group and the first 100 patients of the
CP group were used for this study. Furthermore, during the study
period APTT replaced ACT as the main leading coagulation param-
eter to adjust UFH dosages. The impact of a new leading coagu-
lation parameter could not be assessed, but it may partly explain
the lower UFH infusion rates used in the CP group. Both groups,
however, showed similar median ACT levels despite different main
leading coagulation parameters. Regardless of lower UFH infusion
rates compared to the RP group, the CP group did not show more
thrombotic complications. Finally, while our study findings can be
generalized as ELSO definitions for coagulation complications were
used, there is a lack of clear uniform definitions [2] . The ELSO only
offers a registry list for complications. There is no insight into the
severity and the clinical implications of these complications. In ad-
dition, as discussed before, hemolysis is perhaps unfairly catego-
rized as a hemorrhagic complication. New consensus-based defi-
nitions and categorization of coagulation complications are neces-
sary for accurate interpretation of coagulation issues during ECMO
treatment. Prospective studies into ECMO treatment with standard-
ized care protocols would then be the next step in the more accu-
rate assessment of these coagulation complications. In an effort to
achieve this, our institution is, as of 2019, conducting a prospec-Please cite this article as: Ö. Erdem, J.W. Kuiper, R.J. Houmes et al., Coagula
neonatal and pediatric extracorporeal membrane oxygenation, Journal of Petive study, the CHEKid-study (NL6977), in collaboration with other
ECMO centers, on coagulation monitoring and hemostatic compli-
cations in children receiving ECMO treatment. 
5. Conclusions 
Conversion from an ECMO system with a roller pump to a
different ECMO system incorporated with a centrifugal pump in
neonatal and pediatric ECMO treatment resulted in more hemor-
rhagic complications without severe therapeutic consequences. Se-
rious neurological coagulation complications including intracranial
hemorrhages, the number of circuit changes and outcome did not
significantly differ between the groups. Conversion from an ECMO
system with the roller pump to a different ECMO system incor-
porated with a centrifugal pump appeared to be safe but did not
improve coagulation complication rates or outcome over time. Fu-
ture research on ECMO-related coagulation complications requires
more uniform definitions, taking in consideration the severity and
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